APA

van der Heijde D., Song I., Pangan A. L., Deodhar A., van den Bosch F., Maksymowych W. P., Kim T., Kishimoto M., Everding A., Sui Y., Wang X., Chu A. D. & Sieper J. (20200106). Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. : Lancet (London, England).

Chicago

van der Heijde Désirée, Song In-Ho, Pangan Aileen L, Deodhar Atul, van den Bosch Filip, Maksymowych Walter P, Kim Tae-Hwan, Kishimoto Mitsumasa, Everding Andrea, Sui Yunxia, Wang Xin, Chu Alvina D and Sieper Joachim. 20200106. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. : Lancet (London, England).

Harvard

van der Heijde D., Song I., Pangan A. L., Deodhar A., van den Bosch F., Maksymowych W. P., Kim T., Kishimoto M., Everding A., Sui Y., Wang X., Chu A. D. and Sieper J. (20200106). Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. : Lancet (London, England).

MLA

van der Heijde Désirée, Song In-Ho, Pangan Aileen L, Deodhar Atul, van den Bosch Filip, Maksymowych Walter P, Kim Tae-Hwan, Kishimoto Mitsumasa, Everding Andrea, Sui Yunxia, Wang Xin, Chu Alvina D and Sieper Joachim. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. : Lancet (London, England). 20200106.